These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22682749)

  • 41. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
    Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?
    Schmid-Bindert G; Henzler T; Chu TQ; Meyer M; Nance JW; Schoepf UJ; Dinter DJ; Apfaltrer P; Krissak R; Manegold C; Schoenberg SO; Fink C
    Eur Radiol; 2012 Jan; 22(1):93-103. PubMed ID: 21822784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
    Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions.
    Ding M; Zollinger W; Ebeling R; Heard D; Posey R
    J Appl Clin Med Phys; 2018 Nov; 19(6):226-233. PubMed ID: 30216639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
    Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
    Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
    Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.
    Downey RJ; Akhurst T; Gonen M; Vincent A; Bains MS; Larson S; Rusch V
    J Clin Oncol; 2004 Aug; 22(16):3255-60. PubMed ID: 15310769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The prognostic impact of preoperative PET-CT on postoperative recurrence for completely resected stage I non-small cell lung cancer].
    Qiang G; Xu R; Liu J; Yan J; Xu Y; Di J; Da J; Liang C; Shi B; Guo Y; Liu D
    Zhonghua Wai Ke Za Zhi; 2015 Jul; 53(7):502-7. PubMed ID: 26359072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of stereotactic body radiation therapy for biopsy-proven versus radiographically diagnosed early-stage non-small lung cancer: a single-institution experience.
    Fischer-Valuck BW; Boggs H; Katz S; Durci M; Acharya S; Rosen LR
    Tumori; 2015; 101(3):287-93. PubMed ID: 25908031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study.
    Wiegman EM; Pruim J; Ubbels JF; Groen HJ; Langendijk JA; Widder J
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1059-63. PubMed ID: 21210108
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer.
    Borst GR; Belderbos JS; Boellaard R; Comans EF; De Jaeger K; Lammertsma AA; Lebesque JV
    Eur J Cancer; 2005 Jul; 41(11):1533-41. PubMed ID: 15953716
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer.
    Lopez Guerra JL; Gladish G; Komaki R; Gomez D; Zhuang Y; Liao Z
    J Nucl Med; 2012 Feb; 53(2):225-33. PubMed ID: 22241911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.